Beckley Psytech

atai Life Sciences Announces Update on Beckley Psytech’s phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from phase 1 and First Patients Dosed in phase 2a

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable and shorter treatment paradigm of approximately two hours The phase 2a part of the study will evaluate the safety, tolerability, subjective effects and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12...

First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain

The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic intranasal formulation of the psychedelic 5-MeO-DMT In the study, healthy volunteers will be given both placebo and a 12mg dose of BPL-003 on separate study...
Beckley Park Beckley OXFORD, OX3 9SY United Kingdom